NCIC MA 27: A RANDOMIZED PHASE III TRIAL OF ANASTROZOLE WITH OR WITHOUT CELECOXIB IN POSTMENOPAUSAL WOMEN WITH RECEPTOR POSITIVE PRIMARY BREAST CANCER.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Anastrozole (Primary) ; Exemestane (Primary) ; Celecoxib
- Indications Breast cancer
- Focus Adverse reactions; Therapeutic Use
- 02 Jan 2019 Biomarkers information updated
- 10 Dec 2011 Patient-reported outcomes substudy results presented at the 34th Annual San Antonio Breast Cancer Symposium.
- 05 Oct 2009 Additional lead trial investigator (Carl J. Minniti) identified as reported by New Jersey Cancer Trial Connect record.